PDE4A and chronic obstructive pulmonary disease: Roflumilast, a PDE4 inhibitor with an IC50 of 0.6 nM [3], has been approved in the United States and Europe to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations [6].